Aap Implantate AG Completes Clinical Trial for Antibacterial Technology

In August 2025, aap Implantate AG finalized its human clinical trial for its antibacterial surface technology, funded by the BMBF. Conducted at 13 leading German centers, the study met its safety and equivalence goals, showing positive effects for treated implants compared to untreated ones.

The company is focusing on approvals for antibacterial plates and screws for ankle fractures, with CE and FDA processes underway and plans for China. Initial approval is anticipated by 2028, given regulatory delays. The technology offers potential for healthcare cost savings amid rising infection rates and antibiotic resistance.

Investments and license sales might fund the technology's approval and industrialization. aap aims to expand its license business to various medical fields, boosting its market presence. The company's work is part of a larger effort financed by the BMBF to advance healthcare economics and patient care solutions.